Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Non-Hodgkin lymphoma (NHL), with high aggressiveness and mortality, is one of the top ten
high-incidence tumors in the world and is among the ten most prevalent cancers worldwide with
the fastest growing incidence. Although novel immunotherapies represented by anti-CD20
monoclonal antibodies and CAR-T cell therapies have significantly improved the prognosis of
B-NHL patients, there are still nearly one-third of patients who are resistant to initial
treatment or relapse after remission. Zanubrutinib is an oral small molecule BTK inhibitor,
and has shown good efficacy and safety in multiple subtypes of B-cell lymphoma. However, the
efficacy of zanubrutinib in highly aggressive B-cell lymphoma remains to be further studied